JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging?
Curr Oncol Rep
PUBLISHED: 07-05-2014
Show Abstract
Hide Abstract
As antineoplastic treatment options expand at an increasing rate, both traditional and novel agents continue to be limited by their cardiotoxic effects. While functional decline becomes clinically apparent at late states of toxicity, little is known about early stages during which treatment or prevention may still be an option. Several imaging modalities,including echocardiography, multiple gated acquisition, and cardiac magnetic resonance imaging have the ability to identify cardiac effects before they produce clinical symptoms.Here we discuss the current and future role of cardiac imaging in the assessment of cardiotoxicity of antineoplastic agents. effects on cardiac tissue, resulting in myocardial cellular damage,and ultimately lead to a wide range of effects including electrophysiological abnormalities, symptomatic heart failure(HF), and even death. This represents a limiting factor in the therapy of several otherwise treatable neoplasms [2].The cardiotoxicity of antineoplastic agents raises several important questions regarding the actual prevalence of cardiac toxicity, the ability to effectively treat or prevent such effects with pharmaceutical interventions, and the availability of a means for early diagnosis. Here, we focus on the latter, specifically examining current and potential future imaging strategies to detect the cardiac effects of chemotherapeutic agents.
Related JoVE Video
The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.
Ann. Surg. Oncol.
PUBLISHED: 05-23-2014
Show Abstract
Hide Abstract
Extensive clinical experience suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) may play an important role in the management of colorectal cancer patients with peritoneal carcinomatosis (CRCPC). However, there remains no established nonsurgical process to rationally select patients for this management, either for inclusion/stratification in clinical trials or as a component of standard of care. The Peritoneal Surface Disease Severity Score (PSDSS) was introduced as a basis to improve patient selection.
Related JoVE Video
Restore: the journey toward self-forgiveness: a randomized trial of patient education on self-forgiveness in cancer patients and caregivers.
J Health Care Chaplain
PUBLISHED: 05-03-2014
Show Abstract
Hide Abstract
The present study evaluated "Restore: The Journey Toward Self-Forgiveness," a brief psycho-spiritual curriculum for encouraging self-forgiveness. This was a randomized, wait-list controlled trial including 83 cancer patients and caregivers. Restore encourages self-acceptance, self-improvement, and commitment using prayer/meditation, reflection, and expressive writing in a workbook format. Measures of self-forgiveness, acceptance, self-improvement, and optimism/pessimism were collected before and after participation. Using Analysis of Covariance to control initial levels, post-session levels showed that Restore participants scored higher than wait-list controls on self-forgiveness (F(1,78) = 9.85, p < .001), acceptance (F(1,77) = 4.84, p < .05), and self-improvement (F(1,79) = 5.28, p < .05) and lower than wait-list controls on pessimism (F(1,77) = 5.01, p < .05). Changes in acceptance, self-improvement, and pessimism mediate the Restore effect on self-forgiveness (Beta = -.08, p < .05). This is the first known brief, evidence-based program for facilitating self-forgiveness in patients with self-forgiveness issues.
Related JoVE Video
Initial experience with genomic profiling of heavily pretreated breast cancers.
Ann. Surg. Oncol.
PUBLISHED: 04-30-2014
Show Abstract
Hide Abstract
Rapidly evolving advances in the understanding of theorized unique driver mutations within individual patient's cancers, as well as dramatic reduction in the cost of genomic profiling, have stimulated major interest in the role of such testing in routine clinical practice. The aim of this study was to report our initial experience with genomic testing in heavily pretreated breast cancer patients.
Related JoVE Video
Dangers of "confirmatory" cancer trials that fail to actually test the original hypothesis.
Curr Oncol Rep
PUBLISHED: 02-11-2014
Show Abstract
Hide Abstract
The concept of "confirmatory" studies is a standard and important component of the overall clinical trials strategy in oncology. However, it is critical that such studies are similar enough in basic design and how they are conducted that they actually have the realistic potential to confirm, or refute, objectively the findings of the original study. In this commentary, two examples of clinical studies in the gynecologic oncology arena suggested by some to serve as "confirmatory" trials for the original reports demonstrate both the dangers and potential inappropriateness of such conclusions.
Related JoVE Video
Advances in cervical cancer pharmacotherapies.
Expert Rev Clin Pharmacol
PUBLISHED: 02-04-2014
Show Abstract
Hide Abstract
While widely employed in the management of cervical cancer, the overall utility of systemic anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most studied agent, is currently administered concurrently with external beam radiation as a component of "standard-of-care" in the management of locally advanced cervical cancer. Cisplatin (or carboplatin) combined with paclitaxel is the most commonly utilized regimen in the metastatic/recurrent disease setting (assuming the absence of evidence the cancer is resistant to platinum agents). Recently reported phase 3 trial data have demonstrated that the addition of bevacizumab to either a cisplatin/paclitaxel or paclitaxel/topotecan chemotherapy regimen improves overall survival in metastatic/recurrent cervical cancer.
Related JoVE Video
The incidence of genitourinary and gastrointestinal complications in open and endoscopic gynecologic cancer surgery.
Oncology
PUBLISHED: 02-02-2014
Show Abstract
Hide Abstract
The purpose of this study was to examine the incidence of genitourinary and intestinal tract injuries in an effort to identify which factors might predispose a patient to developing one of these surgical complications.
Related JoVE Video
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Eur. J. Cancer
PUBLISHED: 01-17-2014
Show Abstract
Hide Abstract
Vandetanib is an oral tyrosine kinase inhibitor of VEGFR-2/3, EGFR and RET, which has demonstrated clinical activity as a single agent and in combination with taxanes. We explored the efficacy, safety and toxicity of docetaxel and vandetanib in women with recurrent ovarian cancer (OC).
Related JoVE Video
An Experience with Managing Cancer Patients Reportedly Previously Informed of the Absence of Additional Available Antineoplastic Therapeutic Options.
Case Rep Oncol
PUBLISHED: 01-01-2014
Show Abstract
Hide Abstract
Over the past 5 years, a small group of cancer patients who stated their physicians had determined there were no additional available antineoplastic therapeutic options (including potential investigational strategies) were seen for a 'second opinion' in a cancer hospital-based oncology program and subsequently experienced what can reasonably be characterized as having achieved meaningful 'clinical benefit' (functioning at a fairly high level for a minimum 1 year in the work, home, and/or family environments) following the further delivery of a variety of treatment approaches. While recognized to be limited (or even simply 'anecdotal'), this experience emphasizes several clinically relevant conclusions, including the overall utility of a 'second-opinion' strategy and the potential that the reported statement of an individual practitioner or cancer program that all rational options have been attempted may be inaccurate.
Related JoVE Video
Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: report of two cases.
Case Rep Oncol
PUBLISHED: 01-01-2014
Show Abstract
Hide Abstract
Cyclophosphamide is an alkylating agent widely used in antineoplastic and immunosuppressive therapies. Symptomatic hyponatremia can be a rare but life-threatening complication in patients treated with cyclophosphamide.
Related JoVE Video
Can quality of life assessments differentiate heterogeneous cancer patients?
PLoS ONE
PUBLISHED: 01-01-2014
Show Abstract
Hide Abstract
This research conducted a face validation study of patient responses to the application of an HRQOL assessment research tool in a comprehensive community cancer program setting across a heterogeneous cohort of cancer patients throughout the natural history of diagnosed malignant disease, many of whom would not be considered candidates for clinical research trial participation.
Related JoVE Video
Pegylated liposomal Doxorubicin-induced acute transient encephalopathy in a patient with breast cancer: a case report.
Case Rep Oncol
PUBLISHED: 01-01-2014
Show Abstract
Hide Abstract
Pegylated liposomal doxorubicin (PLD) has a unique pharmacokinetic profile and is widely used to treat a variety of malignancies, alone or in combination with other agents.
Related JoVE Video
Risk of cervical cancer after HPV vaccination.
Curr. Pharm. Des.
PUBLISHED: 08-30-2013
Show Abstract
Hide Abstract
It will likely be more than 20 years before there is unequivocal evidence available that HPV vaccination decreases the incidence of invasive cervical cancer. However, existing data strongly suggests that as many as 440,000 cervical cancer cases and 220,000 deaths due to this malignancy will be prevented with the establishment of an effective worldwide HPV immunization program.
Related JoVE Video
Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer.
Gynecol. Oncol.
PUBLISHED: 03-28-2013
Show Abstract
Hide Abstract
There has been limited change in evidence-based primary chemotherapeutic management of optimal residual advanced ovarian cancer for more than a decade. The backbone of therapy remains a platinum agent (generally carboplatin) and a taxane (generally paclitaxel). Phase 3 randomized trial data provide support for the use of weekly paclitaxel in this setting (compared to the traditional every 3-week schedule) and the addition of bevacizumab as a component of primary management. Recently available data provide increasingly solid support for a role of regional platinum administration in at least a subset of patients with optimal residual advanced ovarian cancer and an important retrospective analysis has suggested a novel biomarker that may predict for the utility (or lack thereof) of this method of drug delivery.
Related JoVE Video
Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer.
J Ovarian Res
PUBLISHED: 02-04-2013
Show Abstract
Hide Abstract
There is no information in the literature on the impact of changes in quality of life (QoL) scores on prognosis in ovarian cancer. We investigated whether changes in QoL during treatment could predict survival in ovarian cancer patients.
Related JoVE Video
Clinically meaningful responses to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer.
Case Rep Oncol
PUBLISHED: 01-29-2013
Show Abstract
Hide Abstract
Pancreatic cancer exhibits profound chemoresistance resulting either from pre-existing (intrinsic) mechanisms, or from anticancer drug treatment itself (acquired chemoresistance). We present the case of a patient with pancreatic adenocarcinoma metastatic to the liver who experienced clinical, radiographic and tumor marker response to three lines of gemcitabine-based chemotherapy. The regimens included: 8 cycles of gemcitabine and oxaliplatin (GEMOX), 8 cycles of gemcitabine, docetaxel and capecitabine (GTX) and more than 3 cycles of gemcitabine and nab-paclitaxel, with an exceptional response 2 years from the initiation of chemotherapy for metastatic pancreatic cancer.
Related JoVE Video
Chemoradiation in the management of cervix cancer: current status and future directions.
Oncology
PUBLISHED: 01-02-2013
Show Abstract
Hide Abstract
Cytotoxic chemotherapy has been shown to have only a very modest impact on outcome in recurrent, persistent, or metastatic cervix cancer. Despite this fact, when cisplatin is administered concurrently with external beam radiation as a chemosensitizing strategy, both progression-free and overall survival have been shown in multiple evidence-based randomized trials to be improved compared to the delivery of radiation alone. Ongoing research in this area has focused on improving the drug component of this strategy and on following the concurrent chemoradiation with systemic (adjuvant) therapy.
Related JoVE Video
New developments in the anti-neoplastic drug management of ovarian cancer.
F1000Prime Rep
PUBLISHED: 01-01-2013
Show Abstract
Hide Abstract
Over the past several years, there have been a number of relevant evidence-based randomized trials that have the potential to change the standard management paradigm in the malignancy of ovarian cancer and (most importantly) enhance clinically relevant outcomes. This commentary will briefly review these trials.
Related JoVE Video
Management of two cases of recurrent anal carcinoma.
Case Rep Oncol
PUBLISHED: 01-01-2013
Show Abstract
Hide Abstract
Due to the low incidence of anal cancer and generally high cure rates, few second-line treatment options have been evaluated in the setting of formal clinical trials. We briefly report two cases that were both found to have wild-type K-RAS, with no epidermal growth factor receptor amplification or evidence of prior persistent human papilloma virus infection. Both cases were treated with irinotecan and cetuximab with evidence of clinical benefit in the setting of a third recurrence, as well as evidence of response to other strategies employed in their management. These cases provide support for the suggestion that treatment planning in conjunction with molecular profiling may be beneficial in such uncommon clinical settings.
Related JoVE Video
Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward.
Nat Rev Clin Oncol
PUBLISHED: 12-20-2011
Show Abstract
Hide Abstract
Highly clinically relevant ovarian cancer clinical research in 2011 focused on an increased understanding of the biology of the malignancy, limitations of strategies for early detection and screening, and the provocative reports of alternative primary and second-line management strategies.
Related JoVE Video
A Case Report of Hodgkins Lymphoma in a Patient with Carcinosarcoma of the Bladder.
Case Rep Oncol
PUBLISHED: 12-14-2011
Show Abstract
Hide Abstract
The screening of patients with a known primary extrathoracic malignancy for pulmonary metastasis may result in the identification of solitary or multiple pulmonary nodules. Radiologic features of these pulmonary nodules may suggest a diagnosis, but these features cannot reliably distinguish between benign and malignant etiologies. We present the case of a patient, diagnosed with carcinosarcoma of the bladder, who was found to have multiple pulmonary nodules by CT evaluation. Physical examination of the patient demonstrated the presence of cervical and axillary lymphadenopathy. An excisional biopsy of an axillary lymph node confirmed the diagnosis of Hodgkins lymphoma. This case report demonstrates that radiographic information obtained by CT scan must be carefully correlated with the history and physical examination of the patient. This case report also demonstrates the importance of diagnostic biopsy of pulmonary nodularity discovered in patients with a known primary extrathoracic malignancy. The assumption that these pulmonary nodules represented metastatic malignancies would have had crucial prognostic and therapeutic implications.
Related JoVE Video
Involvement of bone in epithelial ovarian cancer: case report of an uncommon late metastatic event.
Case Rep Oncol
PUBLISHED: 10-03-2011
Show Abstract
Hide Abstract
Bone involvement is uncommon in epithelial ovarian cancer. In this report, a case of bone metastases from ovarian cancer is described and the potential risk factors for such a rare occurrence are discussed. It is possible that such an event will become more common in the future as patients with advanced ovarian cancer experience prolonged survival but the cancer is not eliminated.
Related JoVE Video
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.
Gynecol. Oncol.
PUBLISHED: 08-01-2011
Show Abstract
Hide Abstract
CA125 is a non-specific marker of peritoneal irritation which has the potential for false elevation during intraperitoneal treatment. The purpose of this study is to identify the rate of CA125 regression during intraperitoneal (IP) versus intravenous (IV) chemotherapy for ovarian cancer.
Related JoVE Video
Synchronous presentation of a primary iliac lymph node plasmacytoma and a prostate adenocarcinoma.
Case Rep Oncol
PUBLISHED: 06-20-2011
Show Abstract
Hide Abstract
Synchronous presentation of primary nodal plasmacytoma and prostate cancer is very rare and has not been described in the literature. Here, we report a case of a patient with nodal plasmacytoma whose clinical presentation was suggestive of metastatic prostate cancer in the setting of recently diagnosed prostate cancer. The workup and treatment of both malignancies as well as a possible underlying common pathologic mechanism (IL-6 gene mutation) are discussed.
Related JoVE Video
Molecular targeted therapy in ovarian cancer: what is on the horizon?
Drugs
PUBLISHED: 06-15-2011
Show Abstract
Hide Abstract
Over the past two decades, empirical optimization of cytotoxic chemotherapy combinations and surgical debulking procedures have improved outcomes and survival in epithelial ovarian cancer. Yet, this disease remains the fifth leading cause of cancer-related deaths in the US, as cure rates seem to have reached a plateau at approximately 20% with conventional chemotherapy. Novel high-throughput genomic and proteomic analyses have improved the molecular understanding of ovarian carcinogenesis, thereby providing a vast array of new potential drug targets with complex signalling interactions. In order to yield the most significant impact on disease outcome, it is necessary to carefully select, and subsequently target, the driving molecular pathway(s) within a tumour or tumour subtype, which are most likely to correspond to high-frequency mutations and genomic aberrations. The identification of biomarkers predictive of response to targeted therapy is essential to avoid poor responses to potentially useful drugs in unselected trial populations. With some promising, albeit early, phase III data on the angiogenesis inhibitor bevacizumab, exciting new opportunities lie ahead with the ultimate goal of personalizing therapies to individual tumour profiles.
Related JoVE Video
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.
Cancer Manag Res
PUBLISHED: 06-10-2011
Show Abstract
Hide Abstract
Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the platinum-resistant setting, and recently reported data reveal the superiority of the combination of PLD plus carboplatin, compared with the platinum drug plus paclitaxel, in delaying the time to disease progression in women with recurrent (potentially platinum-sensitive) disease. Current research efforts involving PLD in ovarian cancer are focusing on adding novel targeted drugs to this cytotoxic agent. The utility of such approaches in the platinum-resistant population, compared with the sequential administration of single agents active in this setting, remains to be determined.
Related JoVE Video
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.
Gynecol. Oncol.
PUBLISHED: 06-03-2011
Show Abstract
Hide Abstract
To elucidate the regulation of MASPIN expression in epithelial ovarian cancer (EOC) and associations with p53 status and MASPIN promoter methylation.
Related JoVE Video
First-line therapy in ovarian cancer trials.
Int. J. Gynecol. Cancer
PUBLISHED: 05-06-2011
Show Abstract
Hide Abstract
At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients. A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)? A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today?
Related JoVE Video
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Gynecol. Oncol.
PUBLISHED: 03-31-2011
Show Abstract
Hide Abstract
Randomized trials have demonstrated significant improvements in progression-free survival (PFS) with consolidation paclitaxel (P) and bevacizumab (B) following cytoreduction and adjuvant carboplatin/paclitaxel (CP) for advanced epithelial ovarian cancer (EOC). We sought to evaluate the cost-effectiveness (C/E) of these consolidation strategies.
Related JoVE Video
Elevated Serum CA-125 in a Patient with Follicular Lymphoma and a History of Ovarian Cancer.
Case Rep Oncol
PUBLISHED: 03-29-2011
Show Abstract
Hide Abstract
A patient with a previous history of epithelial ovarian cancer presented to her physician with diffuse adenopathy. On subsequent evaluation, she was found to have a follicular lymphoma. Work-up revealed an elevated serum CA-125 antigen level, raising the question of whether the laboratory abnormality represented evidence of recurrence of the original epithelial cancer. The subsequent major decline in this tumor marker following treatment directed to the lymphoma provided strong support for the conclusion that the elevated CA-125 was secondary to this malignant process and not ovarian cancer.
Related JoVE Video
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
Gynecol. Oncol.
PUBLISHED: 03-11-2011
Show Abstract
Hide Abstract
To assess the survival impact of initial disease distribution on patients with stage III epithelial ovarian cancer (EOC) cytoreduced to microscopic residual.
Related JoVE Video
Emerging therapeutics for primary peritoneal cancer.
Expert Opin Emerg Drugs
PUBLISHED: 03-01-2011
Show Abstract
Hide Abstract
Primary peritoneal cancer describes a malignancy that originates from the peritoneal lining of the abdomen. The diagnosis is clearest when the ovaries are uninvolved; however, this is rarely the case and, as such, the declaration is often made pathologically by extrinsic or secondary involvement of the ovaries. The disease shares nearly all of the clinicopathologic features of primary ovarian cancer, most importantly, a molecular homology, which has made it unfruitful for considering it a different entity. Because of this, both standard of care treatment algorithms and contemporary drug development protocols nearly uniformly consider these cancers as primary ovarian cancers.
Related JoVE Video
Counterpoint: chemosensitivity assays for recurrent ovarian cancer.
J Natl Compr Canc Netw
PUBLISHED: 01-15-2011
Show Abstract
Hide Abstract
Unfortunately, no reliable evidence-based data have shown any in vitro chemosensitivity assay strategy to be clinically useful in the management of recurrent ovarian cancer, despite frequent use. Several clinical trials have been proposed with the potential to support or refute the relevance of these approaches.
Related JoVE Video
Commentary: Implications of cancer managed as a "chronic illness".
Curr Oncol Rep
PUBLISHED: 01-12-2011
Show Abstract
Hide Abstract
In an increasing number of settings it is appropriate to consider cancer as a very serious but also a chronic disease process. This commentary discusses a number of highly clinically relevant implications of this important evolution in the management of malignancies.
Related JoVE Video
External qigong therapy for women with breast cancer prior to surgery.
Integr Cancer Ther
PUBLISHED: 11-26-2010
Show Abstract
Hide Abstract
The majority of patients with cancer use some form of complementary or alternative medicine. External qigong treatment (EQT), classified as a bioenergy therapy, is one such approach that patients combine with conventional medicine or, in some cases, use in place of conventional medicine. This study aimed to determine whether EQT could shrink breast cancer tumors and improve quality of life (QOL) in women with pathologically confirmed breast cancer awaiting surgery. A total of 9 women with pathologically confirmed breast cancer were recruited from large cancer centers in the United States (n = 5) and China (n = 4). A single-arm pre/post design was used. Each patient underwent 5 consecutive days of EQT, with each treatment lasting from 2 to 5 minutes. All treatments were performed by the same qigong master. Tumor measurements were made before and after the EQT sessions. Tumor assessments were conducted prior to study initiation and following the last EQT. Patients underwent both an ultrasound and mammogram (United States) or an ultrasound and magnetic resonance imaging (China). All patients also underwent physical breast examinations (PBEs) and completed QOL questionnaires before and after the last EQT. No clinical changes in tumor measurements from pre- to post-EQT were noted. There was also no suggestion of change in tumor size by PBE or change in QOL. Using the current
Related JoVE Video
Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer management.
Curr Oncol Rep
PUBLISHED: 08-17-2010
Show Abstract
Hide Abstract
Individual randomized phase 3 trials and meta-analyses of previously published studies have provided support for the general concept of the clinical utility of extending the duration of antineoplastic drug therapy in an effort to prolong ("maintain") a favorable clinical state. This commentary briefly reviews data from several of these reports.
Related JoVE Video
Early onset of platinum hypersensitivity in a dentist: a case report.
Case Rep Oncol
PUBLISHED: 08-12-2010
Show Abstract
Hide Abstract
The very early onset of platinum hypersensitivity reaction in a dentist treated with external beam radiation and weekly carboplatin for a locally advanced squamous cell carcinoma of the skin raises the provocative issue of whether occupational exposure to platinum may have contributed to this most unusual clinical event.
Related JoVE Video
Cisplatin application in pregnancy: first in vivo analysis of 7 patients.
Oncology
PUBLISHED: 07-14-2010
Show Abstract
Hide Abstract
Cervical cancer in pregnancy is an oncologic challenge. Empirical cisplatin is recommended to prevent cancer progression until fetal maturity. Seven patients with cervical cancer in the second trimester decided to delay delivery together with neoadjuvant chemotherapy. After 2-4 cycles, caesarean section and radical hysterectomy were performed above 32 weeks of gestation. Synchronous samples from maternal blood, umbilical cord blood and amniotic fluid were taken. All patients delivered healthy babies. Cisplatin concentrations in umbilical cord and amniotic fluid were 31-65 and 13-42% of the maternal blood, respectively. This is the first series on in vivo cisplatin concentration in the fetomaternal compartment.
Related JoVE Video
Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report.
Case Rep Oncol
PUBLISHED: 07-10-2010
Show Abstract
Hide Abstract
A young woman presenting with an ovarian immature teratoma (stage IA, grade 2) demonstrates the dilemma associated with the decision to withhold adjuvant chemotherapy of documented clinical utility in a setting where highly effective treatment is available should the cancer ultimately recur.
Related JoVE Video
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
J. Clin. Oncol.
PUBLISHED: 07-06-2010
Show Abstract
Hide Abstract
The prevalence of BRCA(1/2) mutations in germline DNA from unselected ovarian cancer patients is 11% to 15.3%. It is important to determine the frequency of somatic BRCA(1/2) changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs.
Related JoVE Video
Recent studies that influence the chemotherapeutic paradigm in the management of advanced ovarian cancer.
F1000 Med Rep
PUBLISHED: 04-27-2010
Show Abstract
Hide Abstract
Several recently reported evidence-based phase 3 trials that focus on the role of cytotoxic chemotherapy have the potential to strongly influence the care of women with advanced epithelial ovarian cancer. Particular areas of interest include: (a) neoadjuvant chemotherapy; (b) chemotherapy of recurrent platinum-sensitive ovarian cancer; and (c) the relevance of paclitaxel scheduling in the primary chemotherapeutic management of the malignancy. This report will briefly discuss the results of these studies and the potential implications of the findings for routine care of patients in these clinical settings.
Related JoVE Video
Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.
Gynecol. Oncol.
PUBLISHED: 03-30-2010
Show Abstract
Hide Abstract
To investigate the feasibility of performing a fresh-tissue, in vitro radiation resistance assay (IVRRA) in a cooperative group setting and to assess the association of IVRRA results with clinical outcomes.
Related JoVE Video
The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy.
Arch. Gynecol. Obstet.
PUBLISHED: 03-22-2010
Show Abstract
Hide Abstract
We investigated if optimal surgical debulking increases tumor responsiveness to maintenance chemotherapy and improves survival in advanced ovarian cancer patients who previously attained a clinical complete response (CCR) to primary chemotherapy.
Related JoVE Video
Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?
Case Rep Oncol
PUBLISHED: 03-13-2010
Show Abstract
Hide Abstract
A woman with heavy pre-treated ovarian cancer sought consultation regarding additional treatments. The case raises the vexing question of whether there may be a time in the course of the disease process where it is most appropriate to state further anti-neoplastic therapy will not be of clinical utility.
Related JoVE Video
Impact of the cost of cancer treatment: an internet-based survey.
J Oncol Pract
PUBLISHED: 02-19-2010
Show Abstract
Hide Abstract
Despite considerable discussion in the medical literature and lay press regarding the increasing cost of cancer care, there is limited information available on the perceived impact of treatment costs on individual patients and their families.
Related JoVE Video
Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma.
Oncology
PUBLISHED: 02-18-2010
Show Abstract
Hide Abstract
Previously reported studies have suggested that maintenance therapy in the treatment of ovarian cancer may provide progression-free survival (PFS) benefits, although they have not discerned a similar impact on patient overall survival (OS).
Related JoVE Video
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
Clin. Cancer Res.
PUBLISHED: 02-09-2010
Show Abstract
Hide Abstract
To safely assess new drugs, cancer patients in initial cohorts of phase I oncology studies receive low drug doses. Doses are successively increased until the maximum tolerated dose (MTD) is determined. Because traditional chemotherapy is often more effective near the MTD, ethical concerns have been raised about administration of low drug doses to phase I patients. However, a substantial portion of oncology trials now investigate targeted agents, which may have different dose-response relationships than cytotoxic chemotherapies.
Related JoVE Video
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Cancer
PUBLISHED: 01-20-2010
Show Abstract
Hide Abstract
Sequential treatment with azacitidine can induce re-expression of epigenetically silenced genes through genomic DNA hypomethylation and reverse carboplatin resistance of epithelial ovarian cancer cells. A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Related JoVE Video
Optimal management of recurrent ovarian cancer.
Int. J. Gynecol. Cancer
PUBLISHED: 12-04-2009
Show Abstract
Hide Abstract
The development of an optimal management approach in recurrent ovarian cancer requires careful consideration of a number of important factors including (a) response to and severity/persistence of toxicity associated with prior therapy, (b) existence of relevant trial data (particularly phase 3 studies), (c) patient interest in participating in clinical trials, (d) cost of (and ability to pay for) particular anti-neoplastic drug regimens, and (e) patient choice. It is likely that the increasing availability of biologically active novel agents (and combination programs) in this clinical setting will add to the difficulty of defining optimal therapy in recurrent/resistant ovarian cancer, which, in many individuals, can be reasonably considered a very serious chronic disease process.
Related JoVE Video
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.
J. Clin. Endocrinol. Metab.
PUBLISHED: 10-09-2009
Show Abstract
Hide Abstract
Thyroid cancer is the most common endocrine malignancy. The outcomes of patients with relapsed thyroid cancer treated on early-phase clinical trials have not been systematically analyzed.
Related JoVE Video
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
Gynecol. Oncol.
PUBLISHED: 09-30-2009
Show Abstract
Hide Abstract
Randomized phase 3 trials have demonstrated the utility of a regimen of carboplatin plus pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer, and have provided provocative data suggesting a substantially lower risk of carboplatin-associated hypersensitivity if PDL is delivered in combination with the platinum agent.
Related JoVE Video
Ovarian cancer.
Lancet
PUBLISHED: 09-28-2009
Show Abstract
Hide Abstract
The standard initial management of epithelial ovarian cancer consists of surgical staging, operative tumour debulking including total abdominal hysterectomy and bilateral salpingo-oophorectomy, and administration of six cycles of intravenous chemotherapy with carboplatin and paclitaxel. Extensive and largely retrospective experience has shown that optimum surgical debulking to leave residual tumour deposits that are less than 1 cm in size is associated with improved patient outcomes. However, 75% of patients present with advanced (stage III or IV) disease and, although more than 80% of these women benefit from first-line therapy, tumour recurrence occurs in almost all these patients at a median of 15 months from diagnosis. Second-line treatments can improve survival and quality of life but are not curative. Advances in screening and understanding of molecular pathogenesis of ovarian cancer and development of novel targeted therapies (eg, bevacizumab) and practical intraperitoneal techniques for drug delivery are most likely to improve patient outcomes.
Related JoVE Video
Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer.
Case Rep Oncol
PUBLISHED: 09-22-2009
Show Abstract
Hide Abstract
A patient with extensive and painful chest wall involvement from a metastatic borderline cancer of the ovary was treated with a carboplatin plus paclitaxel chemotherapy regimen. She achieved a rather dramatic improvement of pain control, a significant biochemical response with 75% reduction of the CA-125 antigen level, but only limited radiographic tumor regression. This experience emphasizes the potential clinical utility of platinum-based cytotoxic chemotherapy in the setting of symptomatic advanced borderline ovarian cancer.
Related JoVE Video
Antiangiogenic drugs in ovarian cancer.
Expert Opin Pharmacother
PUBLISHED: 08-13-2009
Show Abstract
Hide Abstract
There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer.
Related JoVE Video
A Case Report Demonstrating Unambiguous Clinical Utility of Pet/CT Scanning in Recurrent Ovarian Cancer.
Case Rep Oncol
PUBLISHED: 07-29-2009
Show Abstract
Hide Abstract
There has been discussion and debate in the medical literature regarding the clinical value of PET/CT scans in ovarian cancer, particularly focusing on evidence whether the technology is of predictive versus solely prognostic utility. In the somewhat unusual case reported here, the results of the PET/CT scan were extremely helpful in developing a rational management strategy. The case emphasizes the critical need to specifically address the issue of whether data generated from an expensive diagnostic test will be useful in an individual patients management before it is obtained.
Related JoVE Video
Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study.
Oncology
PUBLISHED: 06-28-2009
Show Abstract
Hide Abstract
In vitro testing of the activity of chemotherapeutic agents has been suggested as 1 method to optimally select drugs for patients with ovarian cancer. There are limited prospectively obtained data examining the clinical utility of this approach. We sought to obtain a preliminary assessment of this strategy in a trial that examined the administration of neoadjuvant chemotherapy followed by surgical cytoreduction and intraperitoneal chemotherapy in women with advanced ovarian cancer.
Related JoVE Video
Update on the utility of prognostic biomarkers in ovarian cancer.
F1000 Med Rep
PUBLISHED: 04-29-2009
Show Abstract
Hide Abstract
There is considerable interest in the gynecologic cancer community for the development of biomarkers that will be of utility in routine management of women with advanced ovarian cancer. However, at the present time, there remains limited evidence for the usefulness of any such test other than the serum cancer antigen (CA)-125 level, employed to monitor the course of disease in response to treatment or during periods of observation.
Related JoVE Video
Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma.
Int. J. Gynecol. Cancer
PUBLISHED: 04-28-2009
Show Abstract
Hide Abstract
Maintenance therapy has been extensively studied to discern any prospective therapeutic advantage in the treatment of advanced stage ovarian carcinoma. The CA-125 assay may have prognostic benefit in determining whether this treatment regimen is appropriate for ovarian carcinoma patients who achieve a complete response to first-line therapy. We retrospectively documented the CA-125 levels of 2 advanced ovarian cancer patient groups who exhibited a clinically defined complete response to their primary induction therapy. Patients were then treated with a paclitaxel-based maintenance therapy regimen. The first group (group A; n = 13 patients) received 3 cycles of single-agent paclitaxel maintenance therapy, and the second group (group B; n = 13 patients) received 12 cycles of single-agent paclitaxel maintenance therapy. The premaintenance therapy CA-125 serum levels (<10 or > or =10 U/mL) of the 2 treatment groups were then retrospectively evaluated in an intragroup analysis to discern any relationship with progression-free survival (PFS) and overall survival. There was a statistically significantly relationship between the CA-125 levels (<10 U/mL) premaintenance therapy and PFS. The patients who had the lowest CA-125 levels exhibited the most favorable PFS results. Despite the limited sample size and nonrandomized nature of this study, these results are provocative and suggest that advanced ovarian cancer patients who achieve an excellent response to primary platinum-based chemotherapy with a CA-125 serum level less than 10 U/mL may be more amenable to the benefits of paclitaxel maintenance therapy.
Related JoVE Video
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
Int. J. Gynecol. Cancer
PUBLISHED: 04-28-2009
Show Abstract
Hide Abstract
To assess the association between patient-disease characteristics and overall survival (OS) after second-line intraperitoneal (IP) treatment of ovarian cancer.
Related JoVE Video
An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
Cancer J
PUBLISHED: 04-25-2009
Show Abstract
Hide Abstract
The intraperitoneal delivery of chemotherapy as a strategy to manage epithelial ovarian cancer has been extensively examined in both the preclinical and clinical settings. Several randomized phase 3 trials have documented improved survival associated with regional versus systemic delivery of cisplatin in the primary chemotherapeutic management of small volume residual advanced ovarian cancer. Unfortunately, despite the existence of these evidence-based data, this management strategy remains underutilized. Future research efforts are mandated to develop regimens which improve the toxicity profile of this novel method of treatment while maintaining the documented enhanced efficacy of the approach.
Related JoVE Video
Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience.
Oncology
PUBLISHED: 04-17-2009
Show Abstract
Hide Abstract
Despite the unquestionable importance of clinically oriented research designed to test the safety and efficacy of new therapies in patients with malignant disease, there is limited information regarding strategies to evaluate the quality of such efforts at academic institutions.
Related JoVE Video
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.
Ther Clin Risk Manag
PUBLISHED: 03-26-2009
Show Abstract
Hide Abstract
Both pre-clinical studies and phase 1-2 clinical trials have provided strong support for the potential role of regional drug delivery in the management of epithelial ovarian cancer, a disease process whose major manifestations remain largely localized to the peritoneal cavity in the majority of individuals with this malignancy. The results of 3 phase 3 randomized trials have revealed the favorable impact of primary cisplatin-based intraperitoneal chemotherapy in women who initiate drug treatment with small-volume residual ovarian cancer following an attempt at optimal surgical cytoreduction. Concerns have been raised regarding the toxicity of regional treatment, particularly the side-effect profile associated with cisplatin. One rational approach to improving the tolerability of intraperitoneal chemotherapy is to substitute carboplatin for cisplatin. This review discusses the rationale for and data supporting regional treatment of epithelial ovarian cancer, and highlights the potential role for intraperitoneal carboplatin in this clinical setting.
Related JoVE Video
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
Gynecol. Oncol.
PUBLISHED: 03-10-2009
Show Abstract
Hide Abstract
While primary cisplatin-based intraperitoneal chemotherapy has been shown to favorably impact survival in small-volume residual advanced ovarian cancer, there is a need to develop strategies that improve the effectiveness of this approach.
Related JoVE Video
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
J. Clin. Oncol.
PUBLISHED: 02-27-2009
Show Abstract
Hide Abstract
A message from ASCOS president: Nearly 40 years ago, President Richard Nixon signed the National Cancer Act, mobilizing the countrys resources to make the "conquest of cancer a national crusade." That declaration led to a major investment in cancer research that has significantly improved cancer prevention, treatment, and survival. As a result, two thirds of people diagnosed with cancer today will live at least 5 years after diagnosis, compared with just half in the 1970s. In addition, there are now more than 12 million cancer survivors in the United States--up from 3 million in 1971. Scientifically, we have never been in a better position to advance cancer treatment. Basic scientific research, fueled in recent years by the tools of molecular biology, has generated unprecedented knowledge of cancer development. We now understand many of the cellular pathways that can lead to cancer. We have learned how to develop drugs that block those pathways; increasingly, we know how to personalize therapy to the unique genetics of the tumor and the patient. Yet in 2008, 1.4 million people in the United States will still be diagnosed with cancer, and more than half a million will die as a result of the disease. Some cancers remain stubbornly resistant to treatment, whereas others cannot be detected until they are in their advanced, less curable stages. Biologically, the cancer cell is notoriously wily; each time we throw an obstacle in its path, it finds an alternate route that must then be blocked. To translate our growing basic science knowledge into better treatments for patients, a new national commitment to cancer research is urgently needed. However, funding for cancer research has stagnated. The budgets of the National Institutes of Health and the National Cancer Institute have failed to keep pace with inflation, declining up to 13% in real terms since 2004. Tighter budgets reduce incentives to support high-risk research that could have the largest payoffs. The most significant clinical research is conducted increasingly overseas. In addition, talented young physicians in the United States, seeing less opportunity in the field of oncology, are choosing other specialties instead. Although greater investment in research is critical, the need for new therapies is only part of the challenge. Far too many people in the United States lack access to the treatments that already exist, leading to unnecessary suffering and death. Uninsured cancer patients are significantly more likely to die than those with insurance, racial disparities in cancer incidence and mortality remain stark, and even insured patients struggle to keep up with the rapidly rising cost of cancer therapies. As this annual American Society of Clinical Oncology report of the major cancer research advances during the last year demonstrates, we are making important progress against cancer. But sound public policies are essential to accelerate that progress. In 2009, we have an opportunity to reinvest in cancer research, and to support policies that will help ensure that every individual in the United States receives potentially life-saving cancer prevention, early detection, and treatment. Sincerely, Richard L. Schilsky, MD President American Society of Clinical Oncology.
Related JoVE Video
Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy.
Case Rep Oncol
PUBLISHED: 02-20-2009
Show Abstract
Hide Abstract
The relatively rapid development of a platinum-associated hypersensitivity reaction in an ovarian cancer patient receiving second-line chemotherapy more than a decade following her last course of primary platinum-based chemotherapy demonstrates that the prolonged persistence of immune cells recognizing platinum after sensitization has been established.
Related JoVE Video
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.
Cancer
PUBLISHED: 02-06-2009
Show Abstract
Hide Abstract
There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA-125 antigen levels and prognosis.
Related JoVE Video
The myth of measurable disease in ovarian cancer: revisited.
Cancer Invest.
PUBLISHED: 01-23-2009
Show Abstract
Hide Abstract
There are well-documented and serious limitations associated with analyzing measurable disease in ovarian cancer as a sole primary endpoint in clinical trials, as this focus requires the presence of individual tumor masses of sufficient size and distinctive shape to image. An alternative highly rational strategy adds the routine monitoring of validated serum tumor markers (e.g., CA-125), which can more adequately define changes in "tumor volume" associated with small nonvisualized macroscopic and diffuse microscopic cancer.
Related JoVE Video
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.
Cancer
PUBLISHED: 01-22-2009
Show Abstract
Hide Abstract
The objective of the current study was to determine the prognostic significance of a pretreatment serum CA 125 level in patients with advanced epithelial ovarian carcinoma (EOC) who received treatment with a standard chemotherapy regimen.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.